22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 9
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Rachelle Suzanne Jacques | President, CEO & Director | 632,25k | N/D | 1971 |
Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | 540,34k | N/D | 1967 |
Ms. Melissa Bradford-Klug | Chief Operating Officer | N/D | N/D | 1970 |
Dr. Miles Nunn | Chief Scientific Officer | N/D | N/D | 1969 |
Dr. John F. Neylan III, M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1953 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
L'ISS Governance QualityScore di Akari Therapeutics, Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.